|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, December 25, 2018 ) Anti-Diarrheal medications have been gaining significant traction in non-infectious diarrhea treatment market coupled with oral rehydration solution for preventing or treating loss of fluid. Although oral rehydration solution is expected to burgeon Non-infectious Diarrhea Treatment Market Growth zinc supplementation helps in reducing severity and duration of non-infectious diarrhea treatment. Zinc supplements for non-infectious diarrhea treatment is anticipated to gain significant traction amongst caregivers and children on a larger basis. Furthermore, demand for zinc supplements in non-infectious diarrhea treatment is attracting consumer attention as it offers vital micronutrients that are essential for intestinal transport of electrolytes and water, immune function and protein synthesis.
Request 100 Page Sample Report Now: https://www.factmr.com/connectus/sample?flag=S&rep_id=961
Zinc supplements are not only beneficial for non-infectious diarrhea treatment but also supports in normal development and growth of children. With advantages of zinc supplements in non-infectious diarrhea treatment, lies barriers restraining the non-infectious diarrhea treatment market on a larger basis. Dearth of acceptance of zinc supplements in non-infectious diarrhea treatment by healthcare workers and physicians is likely to restrain the growth of non-infectious diarrhea treatment market. Key players and manufacturers in non-infectious diarrhea treatment market are expected to make heavy investments in R&D for establishing optimal dosage with zinc supplements, especially for children.
Non-infectious diarrhea often lasts for a few days and results in dehydration due to the loss of fluid content in the body. It is a condition that entails at least three or more liquid or loose bowel movements within a day. It often lasts for a few days and results in dehydration due to loss in fluid content of the body. Various non-infectious causes of non-infectious diarrhea include inflammatory bowel disease, lactose intolerance, non-celiac gluten sensitivity, hyperthyroidism, irritable bowel syndrome, bile acid diarrhea and a number of medications. In most cases, stool cultures need not be studied to identify the cause. Globally, approximately 1.7- 5 billion cases of diarrhea occur every year. Non-infectious diarrhea is most common in developing countries where children get diarrhea, on an average, three times a year. Diarrhea accounted for approximately 1.26 million deaths in 2013. It is one of the most common causes of death in children younger than five years in age. Frequent episodes of diarrhea can also cause malnutrition. Other long term problems of non-infectious diarrhea include poor-intellectual development and stunted growth. Non-infectious diarrhea can be improved by sanitation and clean drinking water. Zinc tablets and Oral Rehydration Solution (ORS) - a solution with modest amounts of salts and sugar, are some of the most preferred treatments for non-infectious diarrhea.
Request Full Report with TOC: https://www.factmr.com/report/961/non-infectious-diarrhea-treatment-market
The global market for diverticular disease therapeutics is expected to witness moderate growth over the forecast period. Majority of the products are introduced in the generic market and thus, high competition exists among local and regional players. Among the two treatment types, the anti-diarrheal medication segment is expected to lead the global non-infectious diarrhea treatment market over the forecast period. The drug store distribution channel is expected to contribute a high share in the global non-infectious diarrhea treatment market as it is the most accessible channel and majority of patients are recommended for outpatient treatment.
Geographically, the global non-infectious diarrhea treatment market can be segmented into viz. North America, Latin America, Europe, Asia-Pacific excluding Japan (APEJ), Japan and the Middle East and Africa (MEA). Asia Pacific and Middle-East and Africa are expected to dominate the market for non-infectious diarrhea treatments, owing to the high prevalence of diarrhea. The non-infectious diarrhea treatment market in North America and Latin America is expected to grow at a significant CAGR due to the expansion of product offerings by key players. Europe is expected to hold a considerable share in the global non-infectious diarrhea treatment market throughout the forecast period.
The global market for diverticular disease therapeutics is highly fragmented. Examples of some of the key players operating in the global non-infectious diarrhea treatment market are Abbott Laboratories, Aidarex Pharmaceuticals LLC, Atlantic Biologicals Corps, Major Pharmaceuticals, Proficient Rx LP, Chattem Inc., V.Excel International, ANI Pharmaceuticals Inc. and others.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Ask Industry Expert about this Report - https://www.factmr.com/connectus/sample?flag=AE&rep_id=961
About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market insights reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.
Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Blog: https://factmrblog.com/
Read Industry News at - https://www.industrynewsanalysis.com/
Fact.MR
Sharik
353-1-6111-593
info@factmr.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
